Nexium I.V. (Esomeprazole)

Esomeprazole, the active ingredient in Nexium I.V., is a proton pump inhibitor presented as an intravenous solution for intravenous use. It reduces gastric acid secretion and is employed in the management of gastro‑esophageal reflux disease, erosive esophagitis, and the prevention of NSAID‑induced gastric ulcers.

GNH USA supplies Nexium I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Esomeprazole acts on the gastric proton pump to lower acid production, making it useful for several acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): reduces acid exposure and promotes healing of the esophageal lining. - Erosive esophagitis: accelerates ulcer healing and maintains a low‑acid environment. - Prevention of NSAID‑induced gastric ulcers: provides prophylactic acid suppression to lower ulcer risk.

Adverse reactions may occur with any medication and should be monitored by healthcare professionals.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea - Severe allergic reactions (anaphylaxis, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Elevated liver enzymes - Cardiac arrhythmias (rare)

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function assessment: adjust use in severe impairment. - Hepatic impairment: monitor liver function tests. - Known hypersensitivity: avoid if patient has previous reaction to esomeprazole or other PPIs. - Concomitant use with drugs requiring gastric acidity for absorption: evaluate necessity. - Elderly patients: use with caution due to increased risk of adverse effects. - Store at room temperature: keep in original container, protect from light and moisture.

Esomeprazole may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activity. - Atazanavir: decreased absorption and efficacy. - Ketoconazole: reduced azole absorption.

Moderate Interactions (Monitor Closely): - Digoxin: possible increase in serum digoxin levels. - Methotrexate: reduced clearance leading to higher systemic exposure.